Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial

Autor:	Stuart C. Gordon, Rvikumar Vemuru, Mark Eisner, Jay Cowan, James Ehrlich, Alain Ades, Clifford A. Brass, Micheal David Bernstein, Steve Chen, Donald Hillebrand, Donald Wadland, Lyle Shlager, C. Smith, Lou Gelrud, Mark Levstik, Helen Wong, Stephen A. Harrison, Andrew Nelson, Raj Bhandari, David Dies, Mordechai Rabinovitz, Edward A. Galen, B. Freilich, K. Digregorio, Curt Hagendom, Thomas Hargrave, Paul Bermanski, David Maccini, Samuel B. Ho, Ronald Pruitt, Terence Reisman, Thomas Allen, Robert S. Brown, Michael Cox, David Schulman, Ramsey Cheung, Fred Kilby, J. Lynn Cochran, Thomas McDonald, James Thornton, John Jolley, John Serini, Albert D. Min, Fredrich Loura, Lino Deguzman, Luis Marsano, Robert Finkel, Helen S. Te, Michael G Rahmin, Mark Jonas, Kip Lyche, Jean Luc Szpakowski, George Abraham, Alex D. Lee, Pabak Mukhopadhyay, Firdous Siddiqui, Robert Strauss, William Kaplan, Michael Ryan, Eliot Godofsky, Stephen J. Lanspa, Lawton Shick, Jose Franco, Louis Griffel, Rise Stribling, Avanish Aggarwal, Clive Albert, Thomas Rosenfield, Rockford Yapp, Vijay Balan, Arthur Berman, Nezam H. Afdhal, Maurice Cerulli, Paul Yudelman, Robert Herring, Donate Ricci, Michael Henry, Michael Bloom, Daniel Meline, Barry Migicovsky, Peter Varunok, Peter W Gardner, Gerald Siciliano, Natarjan Bala, Craig J. Peine, P. Kwo, Thomas Noble, David F. Stein, Thuan T. Nguyen, Geoffrey Zucker, Julie E Spivack, John Kichner, Robert G. Gish, Michael Fried, Murali Shankar, Norman Gitlin, James E. Nelson, David Hurwich, Darrell Schwertner, Ronald Wasserman, Douglas D. Dalke, Thai Van Pham, Geronimo Sahagun, Norah A. Terrault, Naoky Tsai, Steven Han, Tarek Hassanein, Thomas Sepe, Seth Richter, Howard Paul Monsour, Micheal Lyons, R. Agrawal, Bennett Cecil, Joseph Polito, Douglas Levin, James Srour, Allan Weston, Larry Weprin, Raymond Kenny, Edward Lebovics, Michael Demicco, Terry Box, Kenneth Diamond, Lawrence Kim, Stephen Kelly, Martin Black, Jeffrey Fenyves, Ellen Shaw, Raymond A. Rubin, James E. Cox, Franco Felizarta, John E. Gross, Ira Lobis, David H. Van Thiel, Bonnie Bock, Lawrence Stein, James D. Lewis, Steven Palley, Ronald Rinker, Joanna Ready, Vinod K. Rustgi, Michael Epstein, David H Berman, Gary Matusow, Walid Baddoura, Gerond Lake-Bakaar, John S. Goff, Scott Wiesen, Neil Brodsky, Fredric Regenstein, Arnold Levin, Bhupinder S. Anand, Stephen Esposito, K. Rajender Reddy, Lisa Ozick, Adil E. Wakil, Karl Esrason, Pierre Nader, David Nunes, David Feldman, K. Ganeshappa, Alan Fixelle, Martha Ghosh, Douglas Brouillette, Victor Araya, Hillel Tobias, David Pound, Louis R. Lambiase, S. Lawrence Rothman, Mark J. Murphy, Jonathan David, James Levin, Steve Carlson, Nathan Kam, Michael S. Dragutsky, Trong Nguyen Tuan, Graham Woolf, Whit Knapple, Donna Goldman, Kenneth R. DeVault, Simon Cofrancesco, Mitchell L. Shiffman, Charles Bedard, Paul Y. Kwo, Rodger Perez, Steven L. Flamm, Keith Tolman, Hulya Levendoglu, Timothy Cavacini, Robert Reindollar, Vance VanDrake, Donald M. Jensen, David Winston, Robert A. Levine, Robert Manning, John R. Lake, John J. Santoro, Scott Becker, Mary Pat Pauly, John M. Vierling, Joseph DePasquale, Jorge Herrera, Diana Sylvestre, Natarajan Ravendhran, Mark Smith, Kevin Dye, M. Davis, Frank Klion, Kevin Behrle, Alan Epstein, William Lyles, Brian K. Hudes, Greg Galler, David I. Bernstein, Jonathon Jensen, Jeffery Cooley, Thomas J. Layden, Carl D'Angelo, Fredric D. Gordon, Myron Brand, David Gabbazaideh, Leon Rigberg, Neville R. Pimstone, Jonathan McCone, Ira M. Jacobson, Tim M Jenkins, John W. King, Harry Matossian, William A. Ross, Rudra Rai
Rok vydání:	2007
Předmět:	Adult Male medicine.medical_specialty Adolescent Genotype Hepatitis C virus Alpha interferon Hepacivirus Interferon alpha-2 medicine.disease_cause Antiviral Agents Gastroenterology Polyethylene Glycols chemistry.chemical_compound Pegylated interferon Internal medicine Ribavirin medicine Humans Prospective Studies Interferon alfa Aged Dose-Response Relationship Drug Hepatology business.industry Body Weight Interferon-alpha Middle Aged Hepatitis C Recombinant Proteins Surgery Treatment Outcome chemistry RNA Viral Peginterferon alfa-2b Drug Therapy Combination Female business Viral load medicine.drug
Zdroj:	Hepatology. 46:971-981
ISSN:	1527-3350 0270-9139
DOI:	10.1002/hep.21932
Popis:	This prospective, multicenter, community-based and academic-based, open-label, investigator-initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in adults with chronic hepatitis C. Patients (n = 5027) were randomly assigned to receive PEG-IFN alfa-2b 1.5 μg/kg/week plus flat-dose (800 mg/day) or weight-based (800-1400 mg/day) RBV for 48 weeks (patients with genotype 1, 4, 5, or 6) and for 24 or 48 weeks (genotype 2/3 patients). Primary end point was sustained virologic response (undetectable [
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f89555848359d2dd8cebe68aa2ab8f14 https://doi.org/10.1002/hep.21932 Zobrazit plný text záznamu Plný text